Enliven Therapeutics

Filed a patent for "fused tetracyclic selective parp1 inhibitors" on Wed, January 25, 2023

Filed a patent for "pyrimidinyl (hetero)aromatic aminopyridine compounds for inhibition of raf kinases" on Fri, January 27, 2023

Filed a patent for "polymorphic forms of (e)-1-((10s)-4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-fluoro-5-methylphenyl)amino)-7,8,10,11-tetrahydro-9h-6,10-methanopyrimido[4',5':5,6]pyrido[3,2-b][1,4,7]oxadiazonin-9-yl)-4-(dimethylamino)but-2-en-1-one" on Mon, May 1, 2023

Filed a patent for "tricyclic pkmty1 kinase inhibitors" on Fri, June 2, 2023

Filed a patent for "fused tetracyclic quinazoline derivatives as inhibitors of erbb2" on Thu, May 25, 2023

Filed a patent for "naphthyridone compounds for inhibition of raf kinases" on Fri, November 4, 2022

Filed a patent for "naphthyridine compounds for inhibition of raf kinases" on Fri, November 4, 2022

Filed a patent for "naphthyridine compounds for inhibition of raf kinases" on Wed, December 7, 2022

Filed a patent for "5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases" on Thu, April 27, 2023

Filed a patent for "sulfone- and sulfoximine-based selective parp1 inhibitors" on Tue, December 20, 2022

Filed a patent for "alkyne quinazoline derivatives as inhibitors of erbb2" on Thu, August 24, 2023

Filed a patent for "7-azaindole compounds for inhibition of bcr-abl tyrosine kinases" on Thu, February 8, 2024

Filed a patent for "fused tetracyclic quinazoline derivatives as inhibitors of erbb2" on Thu, November 30, 2023

Filed a patent for "lactam (hetero)arylfusedpyrimidine derivatives as inhibitors of erbb2" on Thu, April 11, 2024

Filed a patent for "5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases" on Thu, November 30, 2023

Filed a patent for "naphthyridone compounds for inhibition of raf kinases and/or bcr-abl tyrosine kinases" on Thu, August 29, 2024

Filed a patent for "polycyclic quinazolines for inhibition of erbb2" on Tue, September 13, 2022

Filed a patent for "naphthyridine compounds for inhibition of raf kinases" on Thu, August 25, 2022

Filed a patent for "fused tetracyclic quinazoline derivatives as inhibitors of erbb2" on Tue, October 18, 2022